Royalty Pharma plc
RPRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$64.76
KIRA · Stoqly’s AI analyst, in plain words
- Royalty Pharma plc had $2.4B of revenue in fiscal 2025, up 5.1% on the year before. Over five years, revenue changed +2.3% a year on average.
- Its operating margin was 65.6%, up 8.5 pts: of every 100 in sales, about 66 is left after running the business.
- Royalty Pharma plc made $771M of net profit in fiscal 2025.
- Royalty Pharma plc returned $1.2B to shareholders in fiscal 2025. The diluted share count fell 5.0%.
- Royalty Pharma plc owes $8.3B more than it holds in cash, about 5.3 years of operating profit.
Market cap
$36.1B
P/E
34.6x
Revenue
$2.4B
Net income
$771M
Free cash flow
—
Operating margin
65.6%
Royalty Pharma plc in 30 seconds · fiscal 2025
Are sales growing?
+5.1%
Yes. Sales grew 5.1% last year.
Does it make a profit?
32.4%
Yes. It keeps 32.4% of every sale as profit.
Is debt under control?
5.3x
Heavy. Repaying its debt would take 5.3 years of operating profit.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
34.6x
One share costs 34.6 times its yearly profit per share.
What Royalty Pharma plc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 11, 2026
- Legal name
- Royalty Pharma plc
- CIK
- 0001802768
Royalty Pharma plc · RPRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.3B | $2.2B | $2.4B | $2.3B | $2.4B |
| Revenue growth | 7.9% | −2.3% | 5.2% | −3.9% | 5.1% |
| Operating margin | 62.5% | 13.7% | 63.4% | 57.1% | 65.6% |
| Net income | $620M | $42.8M | $1.1B | $859M | $771M |
| Net margin | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
| Diluted EPS | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
| Cash | |||||
| Cash from operations | $2.0B | $2.1B | $3.0B | $2.8B | $2.5B |
| Share buybacks | $0.0M | $0.0M | $305M | $230M | $1.2B |
| Share count change | 10.5% | 5.6% | 37.7% | −1.5% | −5.0% |
| Debt and strength | |||||
| Cash and short-term investments | $1.6B | $1.7B | $495M | $987M | $637M |
| Debt incl. finance leases | $7.1B | $7.1B | $6.1B | $7.6B | $9.0B |
| Shareholders' equity | $10.2B | $9.5B | $10.1B | $10.3B | $9.7B |
| Net debt / EBITDA | — | — | 3.8x | 5.1x | 5.3x |
| Current ratio | 16.8x | 2.2x | 7.9x | 1.4x | 2.4x |
| Interest coverage | 8.6x | 1.6x | 8.0x | 5.7x | 5.1x |
| Returns and quality | |||||
| Return on capital | 9.1% | 2.1% | 9.5% | 7.6% | 8.7% |
| Return on equity | 6.2% | 0.4% | 11.6% | 8.4% | 7.7% |
| Return on tangible equity | 6.1% | 0.4% | 11.3% | 8.3% | 8.8% |
| Piotroski F-score | 4 | 4 | 7 | 4 | 5 |
| Altman Z'' | 3.5 | 2.4 | 3.2 | 2.6 | 2.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$92.8M
5 insiders
Of sales under plans
100%
$92.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Royalty Pharma plc · RPRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $64.76 a share, the company is worth $36.1B: 34.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001802768). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.